drugset / Trial / NCT04013334
MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma
Phase 2
Unknown
12 enrolled
Momotaro-Gene Inc.
Baylor College of Medicine · collabSynteract, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
Twelve patients with relapsed malignant pleural mesothelioma will be treated with intratumoral injections of MTG201, a replication incompetent adenovirus, modified by the insertion of the reduced expression in immortalized cells (REIC)/Dikkopf (Dkk)-3 gene, on Days 1, 8, 22, and 50. Patients will also receive every 4 weekly intravenous infusions of nivolumab, 480 mg, starting on Day 2. Safety and anti-tumor activity will be monitored at regular intervals throughout the study.
Timeline
- Start
- 2019-08-15
- Primary completion
- 2022-12-31
- Completion
- 2023-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MTG201 | Unknown | 3e+12 vg | Other |
| Subject | Nivolumab | Monoclonal antibody | 480 mg | Intravenous |